Purpose CD27, a costimulatory molecule on T cells, induces intracellular signals that mediate cellular activation, proliferation, effector function, and cell survival upon binding to its ligand, CD70. Varlilumab is a novel, first-in-class, agonist CD27 antibody that stimulates the CD27 pathway, which results in T-cell activation and antitumor activity in tumor models. This first-in-human, dose-escalation and expansion study evaluated the safety, pharmacology, and activity of varlilumab in patients with advanced solid tumors.
Purpose CD27, a costimulatory molecule on T cells, induces intracellular signals that mediate cellular activation, proliferation, effector function, and cell survival upon binding to its ligand, CD70. Varlilumab is a novel, first-in-class, agonist CD27 antibody that stimulates the CD27 pathway, which results in T-cell activation and antitumor activity in tumor models. This first-in-human, dose-escalation and expansion study evaluated the safety, pharmacology, and activity of varlilumab in patients with advanced solid tumors.
Methods
In a 3 + 3 dose-escalation design (n = 25), patients received a single dose of varlilumab (0.1, 0.3, 1.0, 3.0, or 10 mg/kg intravenously) with a 28-day observation, followed by up to five multidose cycles (one dose per week for 4 weeks), depending on tumor response. Expansion cohorts were initiated at 3.0 mg/kg in patients with melanoma (n = 16) and renal cell carcinoma (RCC; n = 15). Primary objectives were to assess the safety and the maximum tolerated and optimal biologic doses of varlilumab. Secondary objectives were to evaluate the pharmacokinetics, pharmacodynamics, and clinical antitumor activity of varlilumab.
Results
Exposure to varlilumab was linear and dose proportional across dose groups. Only one patient experienced a dose-limiting toxicity-grade 3 transient asymptomatic hyponatremia at the 1.0-mg/kg dose level. Treatment-related adverse events were generally grade 1 or 2 in severity. Evidence of biologic activity consistent with CD27 stimulation-chemokine induction, T-cell stimulation, regulatory T cell depletion-was observed at all dose levels. A patient with metastatic RCC experienced a partial response (78% shrinkage, progression-free survival . 2.3 years). Eight patients experienced stable disease . 3 months, including a patient with metastatic RCC with progression-free survival of . 3.9 years.
Conclusion
Dose escalation of varlilumab to 10 mg/kg was well tolerated without identification of a maximum tolerated dose. Varlilumab was biologically and clinically active.
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INTRODUCTION
Immunotherapy that targets T-cell checkpoint pathways has validated the concept of engaging the immune system in the war against cancer and has changed the treatment and outcome for many patients with cancer. 1 This concept of removing the brake relies on an active immune response that is being held back by these powerful regulatory pathways. In many patients with cancer, the immune system's recognition and response to the tumor requires help to initiate and maintain productive antitumor T cells. Agonist antibodies to costimulatory molecules that promote the generation of antitumor T cells have the potential to add to the immunotherapeutic approach to cancer.
CD27, a member of the tumor necrosis factor receptor superfamily, acts as a potent costimulatory molecule that, unlike other related family members, is expressed constitutively on unstimulated T lymphocytes. CD70, the ligand for CD27, is transiently expressed on antigen-presenting cells. CD27-CD70 mediated costimulation-concomitant with antigen-specific T-cell receptor (TCR) stimulation-results in T-cell activation, proliferation, survival, and maturation of effector capacity and T-cell memory. 2, 3 CD27-CD70 interactions also promote B-cell proliferation, generation of plasma cells, production of immunoglobulin and B-cell memory, [4] [5] [6] [7] and induction of the cytolytic activity of natural killer (NK) cells.
8 CD27 is also expressed by regulatory T cells (Tregs) that can be associated with the suppression of antitumor immunity 9 and may have a role in their expansion and activation.
10
Varlilumab (CDX-1127) is a novel, first-in-class, fully human IgG1k anti-CD27 monoclonal antibody that acts as an agonist of CD27 and reacts with the ligand binding site of CD27 as demonstrated by inhibition of CD70 binding to CD27.
11 Varlilumab enhances the CD27-mediated lymphocyte costimulatory pathway but does not directly activate lymphocytes in the absence of signaling through the TCR as shown with in vitro lymphocyte proliferation and cytokine induction studies. Varlilumab has an unmodified Fc region and can also mediate Fc-dependent effector functions. In human CD27 transgenic mice, varlilumab has potent antitumor immunity in multiple models, which provides the rationale for its clinical development.
12
This first-in-human, phase I, open-label, dose-escalation and expansion study was conducted to assess the safety, pharmacokinetics, pharmacodynamics, and activity of varlilumab when administered as monotherapy to patients with advanced malignancies. Patients with solid tumors and hematologic malignancies were separately enrolled in parallel dose-escalation and expansion phases, given the potential for differing mechanisms of action, pharmacokinetics, and toxicity profiles of anti-CD27-directed therapy in these populations. This report describes the results of evaluations of patients with solid tumors.
METHODS
Patients
The study was open to patients with metastatic melanoma, renal cell carcinoma (RCC), hormone-refractory prostate adenocarcinoma, ovarian cancer, colorectal adenocarcinoma, or non-small-cell lung cancer progressive subsequent to previous therapies with no remaining alternative approved therapy options. Patients with melanoma who enrolled in the expansion cohort must have received or refused ipilimumab and, if expressing the BRAF V600E mutation, vemurafinib. Additional eligibility requirements are provided in the Appendix (online only).
The study was conducted at each of the participating institutions in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines after approval by a local human investigations committee and in accordance with an assurance filed with and approved by the Department of Health and Human Services, where appropriate. All patients provided written informed consent before any protocol-specific procedures.
Study Design and Treatment
The study consisted of a standard 3 + 3 dose-escalation phase, 13 followed by tumor-specific expansion cohorts to explore the clinical and biologic activity of varlilumab in distinct patient populations. Study design and treatment schema are shown in Appendix Figs A1 and A2 (online only). Primary study objective was to assess the safety and tolerability profile of single and multiple doses of varlilumab and, if possible, to determine the maximum tolerated dose and/or optimal biologic dose in patients with solid tumors. Secondary objectives were to determine the pharmacokinetics, pharmacodynamic profile, and immunogenicity of single and multiple doses of varlilumab. Varlilumab dose levels of 0.1, 0.3, 1.0, 3.0, and 10 mg/kg were selected for dose escalation on the basis of the no observable effect level of 25 mg/kg that was identified during nonclinical toxicology as well as to bridge the dose ranges with expected clinical activity. Varlilumab was initially administered as a single dose followed by a 4-week evaluation period. Additional multidose treatment (one dose per week for 4 weeks with a 4-week observation) and retreatment (up to four additional cycles, each consisting of one dose per week for 4 weeks, with an 8-week observation) were allowed for patients with stable disease. Varlilumab was permanently discontinued upon confirmed disease progression or dose-limiting toxicity (DLT). Patients with confirmed tumor response discontinued varlilumab, were observed for response duration, and were eligible for additional cycles of treatment at the time of relapse. DLT was defined as any grade $ 3 treatment-related toxicity, excluding the following: grade 3 inflammation as a result of local therapeutic response persisting # 7 days; grade 3 nonmalignant lymphocyte changes that improve to grade # 2 or within 20% of baseline within 28 days; and grade 3 nausea, vomiting, or diarrhea that resolve to grade # 1 within 48 hours.
After evaluation of safety, pharmacodynamics, and early activity data from the dose-escalation component of the study, two expansion cohorts, one consisting of 16 patients with melanoma and one consisting of 15 patients with RCC, were treated with varlilumab 3.0 mg/kg to further evaluate its antitumor activity. The dose of 3 mg/kg was selected to ensure receptor saturation and was based on a consistent immune activation profile in patients who were treated at the dose level. These patients received up to five cycles of varlilumab, each administered as one dose per week for 4 weeks with an 8-week observation.
Varlilumab was administered as a 90-minute intravenous infusion without prophylactic premedication. Dose-escalation patients received the first dose of varlilumab as a split dose, in which a 10% test dose that was infused over 10 minutes was followed by a 1-hour observation before administration of the remaining dose. All patients were monitored for 4 to 6 hours after the first two infusions and for 2 hours after each subsequent dose.
Assessments
Safety assessments included physical exams, vital signs, hematology, blood chemistry, urinalysis, thyroid function, C-reactive protein, immunoglobulin, autoimmune panel, and ECG. Patients were monitored through 70 days post-treatment for such events as diarrhea, colitis, rash, endocrinopathies, and hepatitis, which may occur secondary to activation of the immune system.
14 Toxicity was graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
Antitumor activity was assessed by investigators according to the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).
15
Restaging of assessments were performed every 12 weeks.
Serum samples were obtained at various time points for pharmacokinetic, antidrug antibodies, cytokine and chemokine, and soluble CD27 analysis. Whole blood was collected and processed into peripheral blood mononuclear cells (PBMCs) and frozen for subsequent analysis by flow cytometry and ELISpot as previously described 16, 17 (Appendix Fig A3,  online only) . Paired fresh tumor biopsy specimens was optional and obtained from a single patient.
were used to refine the terminal phase for each patient. Area under the curve was calculated by the linear trapezoidal rule with linear interpolation. All calculations were based on actual sampling times and infusion durations. For pharmacodynamic end points, significant differences were calculated by two-tailed t tests using paired or unpaired data as indicated in figure legends.
RESULTS
Patient Characteristics
Fifty-six patients were enrolled at nine centers from October 31, 2011, to March 5, 2014 . The dose escalation component of the study included 25 patients, whereas 16 patients with melanoma and 15 patients with RCC were enrolled in expansion cohorts. The most frequent tumor type in the dose-escalation phase was colorectal cancer (40%) followed by melanoma (28%). All patients had stage IV disease. Patients, in general, were heavily pretreated. Patients in the dose-escalation phase had received a median of five prior lines of anticancer therapy. Most patients (81%) in the melanoma expansion cohort had received prior checkpoint blockade (primarily anti-cytotoxic T-cell lymphocyte-4 targeted therapy), whereas all patients in the RCC expansion cohort had received tyrosine kinase inhibitors (Appendix Table A1 , Online only).
Study Treatments and Tolerability
Varlilumab was well tolerated. Patients received a median of four (range, one to 21) varlilumab doses on study, with 10 patients receiving more than one cycle of treatment. Dose escalation completed through 10 mg/kg without identification of a maximum tolerated dose. A single DLT-grade 3 asymptomatic hyponatremia (129 mmol/L)-occurred at the 1.0-mg/kg dose level. The event, with onset 14 days after the single dose of varlilumab, spontaneously resolved. No additional patients discontinued varlilumab as a result of toxicity. Treatment-related toxicities-generally grade 1 and 2-included fatigue, rash, nausea, and diarrhea (Table 1) . Grade 3 treatment-related events were limited to one case each of hyponatremia (the DLT discussed above), decreased Any event 25 (100) 14 (56) 16 (100) 8 (50) 15 (100) 10 (67) 56 (100) 32 (57 (56) 2 (8) 12 (75) 1 (6) 10 (67) 1 (7) 36 (64) 
NOTE. Data shown as No. (%). Table presents all-causality adverse events with incidence of . 10% and treatment-related adverse events with incidence of . 5% overall or with any instance of severity grade $ 3. No grade 5 treatment-related adverse events were reported. *Laboratory abnormalities were reported as adverse events if clinically significant. According to laboratory data, 16 (51%) of 31 patients in expansion cohorts had at least one grade worsening in lymphocyte count.
appetite, and decreased lymphocyte count. An additional patient with history of asthma, lung metastases, and previous grade 4 anti-programmed death-1 monoclonal antibody-associated infusion reaction, including bronchospasm, experienced grade 4 asthma and bronchospasm that led to hospitalization. Two patients experienced grade 2 infusion reaction associated with varlilumab administration and received additional varlilumab infusions with premedication, including corticosteroid, antihistamine, and acetaminophen without further reactions.
Pharmacokinetics and Pharmacodynamics
After initial dosing, mean peak serum levels of varlilumab ranged from 3.6 mg/mL (0.1 mg/kg) to 357 mg/mL (10 mg/kg; Fig 1A and Appendix Table A2 , online only). Exposure was dose proportional, with mean T 1/2 ranging from 2.7 days (0.3 mg/kg) to 10.5 days (10 mg/kg) after day 1 dosing. After steady-state dosing, T 1/2 ranged from 4.8 days (0.3 mg/kg) to 19.3 days (10 mg/kg). Only the lowest dose level of varlilumab (0.1 mg/kg) resulted in complete clearance of the antibody within 28 days, which also corresponded to a loss of detectable surface-bound antibody on circulating T cells (Fig 1B) . Doses of $ 1 mg/kg resulted in near saturation of T cells for at least 1 month. Furthermore, samples from a patient with pre-and ontreatment biopsies (3-mg/kg dose) showed evidence of varlilumab bound to T cells that were isolated from the tumor ( Fig  1C) . Patients showed a significant and dose-dependent increase in levels of soluble CD27, which likely reflects stabilization of shed CD27 in serum (Fig 1D) . Antidrug antibodies were not detected.
The effect of varlilumab on the levels of circulating cytokines, chemokines, and growth factors was determined by cytokine bead array. Significant changes in a broad spectrum of molecules that generally peaked within a few hours after administration were observed at all dose levels (Fig 2A and Appendix Fig A4, online only) . The full panel for the nine patients who received 1 mg/kg is shown as a heat map in Fig 2A and indicates the transient and predominantly proinflammatory nature of the response. Among molecules tested, interferon gamma (IFN-g) -induced protein 10 (IP-10 or CXCL10) was most prominently increased and without a clear dose relationship (data not shown). Increases in IP-10 were more profound after the initial dose compared with the final dose of the cycle, which suggested potential desensitization (Fig 2B) .
Varlilumab administration was associated in some patients with generally low-grade lymphopenia that was stable during continued treatment and not associated with a clear dose effect. In expansion cohorts, 16 (51%) of 31 patients had at least one grade worsening in lymphocyte count. There was no consistent effect observed in CD8 + T-or B-cell numbers, whereas CD4 + T cells were consistently reduced among most patients, regardless of dose level (Fig 3A) . Decline in CD4 + T cells was correlated with a significant decrease in CD4 + Tregs that was maintained or further decreased through the treatment cycle ( Figs 3B and 3C ). Approximately one half of patients had a marked and sustained increase in NK cells, which were CD56 dim, a phenotype associated with cytotoxic NK cells (Fig 3A and data not shown) . Varlilumab treatment changed the relative ratios and activation status of naïve, memory, and effector T cells. Among CD8 + T cells, there was a decrease in the percentage of naïve cells and an increase in the terminally differentiated effector memory subset (Appendix Fig A5, online only) . Similarly, CD4 + T cells had lower numbers of cells with a naïve phenotype, with increased numbers of effector memory cells. These changes correlated with an increased expression of the activation marker, HLA-DR, that was most prominent on circulating CD4 + T cells (Fig 4) , but also apparent on tumor infiltrating T cells (not shown) and confirmed by upregulation of other activation makers, including CD69, 4-1BB (CD137), and ICOS (CD278) (data not shown). Consistent with changes in the T-cell activation profile, we also observed increased responses to recall antigens and phytohemagglutinin in a number of patients as monitored by IFN-g ELISpot assays (Appendix Fig  A6, online only) .
To investigate the effect of varlilumab on antigen-specific T-cell responses, we looked for evidence of T-cell reactivity by IFN-g ELISpot with suspected melanoma antigens in patients with melanoma with relevant HLA type. Of interest, we observed both augmentation of preexisting and induction of de novo responses in a subset of patients (Fig 5) . Of particular interest was the development of a de novo response to a MAGE-A1 peptide, which was also confirmed by using pentamer staining (patient 04-9002).
Antitumor Activity
One patient in the RCC expansion cohort who had previously received three lines of treatment for stage IV disease experienced durable and significant tumor regression (Appendix Fig A7, online  only) . After a partial response after the first cycle of varlilumab and discontinuation of varlilumab at 5.5 months, tumor volume was further reduced with 78% shrinkage of target lesions, including Changes in serum factors after varlilumab administration. (A) Heatmap illustration of changes in cytokines, chemokines, and growth factors in serum from nine patients who received varlilumab at 1 mg/kg. P values for changes at the 2-hour timepoint versus baseline by two-tailed paired t test are indicated. *P # .05; **P # .01; ***P # .001. (B) Interferon gamma-induced protein 10 (IP-10) serum levels at baseline and 6 hours after the first or last varlilumab dose from patients with available samples.
complete resolution of lung and paraortic lymph lesions. Partial response persists at 2.3 years without further anticancer therapy. A second patient with RCC completed five cycles of varlilumab (3 mg/kg), experienced 18% shrinkage of target lesions, and has maintained stable disease for 3.9 years without additional therapy. The patient had previously experienced disease progression after 3 months on everolimus and sorafenib and after 9 months on capecitabine.
Eight patients experienced stable disease for . 3 months on study, including four patients with RCC (duration of stable disease: 5.3, 5.6, 9.3, and $ 47.3 months), three patients with melanoma (3.8, 7.3, and 11.5 months) , and one patient with colorectal adenocarcinoma (5.7 months). A patient with metastatic uveal melanoma with stable disease underwent resection of an enlarging axillary node at 7.5 months, then continued to receive varlilumab with remaining lesions stable until 11.5 months. The patient had previously lost benefit from ipilimumab at 6 months and temozolomide at 4 months.
DISCUSSION
In this first-in-human study of varlilumab-a novel, first-in-class, agonist anti-CD27 monoclonal antibody-dosed at 0.1 to 10 mg/ kg was well tolerated by patients with advanced solid tumor malignancies. Pharmacokinetic analysis demonstrated significant and sustained exposure to varlilumab during treatment cycles. Pharmacokinetics did not seem to be impacted by an increase in circulating sCD27 associated with higher doses of varlilumab. The increase in sCD27, which is presumed to be complexed with the jco.org much higher levels of varlilumab, likely represents slower clearance mechanisms, perhaps similar to those described for the increase in vascular endothelial growth factor during bevacizumab treatment. 18 Of importance, there was no evidence of high-grade hepatitis, colitis, or pneumonitis or other high-grade immunerelated adverse events that have been associated with immune stimulatory monoclonal antibodies that target costimulatory or checkpoint pathways. 19 This favorable safety profile is consistent with the restricted lymphocyte-specific expression of CD27, the requirement for concomitant TCR engagement to induce T-cell + T-cell responses in HLA-A2-or HLA-A3-positive patients with melanoma to the indicated melanoma-associated antigens. Peripheral blood mononuclear cells (PBMCs) from days 1, 29, and 85 were assayed for interferon-gamma production in response to antigen-presenting cells that were pulsed with selected melanoma antigen peptides after 2 weeks in vitro stimulation with a peptide cocktail. Values shown are the fold change on the basis of dividing the absolute counts for each peptide by the counts with control HIV gag-derived peptides. P values were calculated by using one-way analysis of variance for individual timepoints or unpaired Student t tests across timepoints. For patient 04-9002, PBMCs were directly stained for major histocompatibility complex multimer binding and representative dot plots are presented. ns, not significant. activation in conjunction with CD27 stimulation, and the safety of varlilumab in preclinical studies.
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Varlilumab demonstrated evidence of biologic activity that was aligned with targeting and activation of the CD27 pathway. Consistent with our previous results using varlilumab for in vitro activation of human T cells, 20 a transient increase in proinflammatory mediators, particularly IP-10, was observed across all dose levels (data not shown). IP-10 has been recognized as an important cytokine whose expression is upregulated by CD27 costimulation in CD8 + T cells. 21 In addition, we observed an increase in circulating T cells with an activated phenotype and a change to fewer naïve T cells and more effector T cells. In selected patients with melanoma, increases in T cells that recognize melanoma-related antigens were observed by ELISpot and confirmed by pentamer staining. Most notable was a consistent decrease in circulating Tregs, which is also observed in our preclinical studies and is linked to its antitumor activity in some models (Wasiuk A, manuscript in preparation). Although we understand that Fc receptor interaction is required for efficient cross-linking and activation of CD27 by varlilumab, 11 it is unclear whether the decrease in circulating Treg is the result of Fc receptor-mediated effector function or an alternative effect. Collectively, these data support the concept that varlilumab is effectively engaging its target, CD27, which leads to activation of this pathway.
One patient with RCC achieved a durable partial response, with post-treatment tumor regression continuing beyond 2 years, a pattern characteristic of immunotherapy. Another patient with RCC continues to experience stable disease at nearly 4 years, and several additional patients with various cancer types demonstrated tumor regression or stable disease. The modest clinical activity of varlilumab monotherapy is similar to previously reported data with antibodies that targeted related costimulatory molecules, 4-1BB 22 and OX40, 23 and underscores the importance of combination therapy to engage multiple aspects of the cancer-immunity cycle. It should also be noted that the immunologic assessments did not identify an optimal biologic dose for varlilumab, and potentially better activity could be observed with less frequent or lower dosing as there was a trend toward more consistent biomarker changes in the dose-escalation phase of the study. Likewise, less frequent dosing correlated with better outcomes for a CD40 agonist antibody in patients with cancer. 24, 25 This phase I study of varlilumab provides proof of concept and a rationale for further study in combination with immunotherapies and traditional therapies. Therapy that targets multiple nonredundant pathways that regulate immune responses may be synergistic and enhance antitumor immune responses. Similarly, combining varlilumab with agents that induce the release of tumor antigens from dying cancer cells can promote new antitumor T-cell responses. On the basis of preclinical models that support synergy of varlilumab with either checkpoint blockade or chemotherapy regimens, 26 a broad clinical evaluation of varlilumab with combination therapy is underway.
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Disclosures provided by the authors are available with this article at jco.org. Terminally differentiated Naive CD56 CD45RA CCR7 CCR7 Fig A3. Flow cytometry gating strategy and methods. For surface staining, peripheral blood mononuclear cells or TIL were thawed at 37°C, washed, and plated in 96-well V-bottom plates. Thawed cells were stained according to the manufacturer's directions (ThermoFisher). Briefly, cells were washed in PBS and set at 1e6/ml in PBS with 1:1000 dilution of fixable live/dead Aqua for 30 minutes on ice in the dark. Cells were washed twice with PBS prior to further staining with a cocktail of fluorescently labeled antibodies that were specific for the following: CD13 and CD14 (exclusion gate); CD19, CD3, CD8, CD56, CD45RO,CD45RA, CD27, CD25, and HLA-DR (antibodies from BD, eBioscience, and BioLegend). After incubation, cells were washed, incubated in Fix/Lyse (Becton Dickenson) for 10 minutes, and resuspended in fluorescent-activated cell sorting buffer for flow cytometry. For detection of FoxP3, cells were surface stained as above, fixed, and permeabilized in FoxP3 staining buffer (eBioscience), then incubated with anti-human FoxP3. CD3 + cells were also separately stained for differentiation status using CD8, CD45RA, and CCR7 as shown. Labeled cells were washed with Permwash buffer before final fixation. Stained samples were acquired using a LSR Fortessa running DIVA 6.0 (Becton Dickenson) and analyzed using FlowJo (Treestar, Ashland, OR). NK, natural killer; SSC, side scatter; Treg, T regulatory cell. 
